Zhong-Zhe Lin - Concepedia

Author

Zhong-Zhe Lin

National Taiwan University Hospital

Also Known As

Zhong-Zhe Lin

Publications

615

Citations

H-Index

Concepts

All Affiliations

National Taiwan University Hospital National Taiwan University National Yang Ming Chiao Tung University National Cheng Kung University Hospital National Cheng Kung University

About

Zhong-Zhe Lin is an author at National Taiwan University Hospital specializing in medicine, oncology, and cancer therapeutics.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	6	6	155
2	Cell Biology	2	2	58
3	Nursing	1	1	16
4	Family Medicine	1	1	16
5	Hepatology	1	1	26

Zhong-Zhe Lin

Publications

608

Citations

H-Index

Page 1

	Year	Citations
First-in-Human Phase I Study of Fisogatinib (BLU-554) Validates Aberrant FGF19 Signaling as a Driver Event in Hepatocellular Carcinoma Richard D. Kim, Debashis Sarker, Tim Meyer, Cancer Discovery	2019	239
Efficacy of a novel histone deacetylase inhibitor in murine models of hepatocellular carcinoma Yen‐Shen Lu, Yoko Kashida, Samuel K. Kulp, Hepatology	2007	90
A phase II study of the efficacy and safety of the MET inhibitor capmatinib (INC280) in patients with advanced hepatocellular carcinoma Shukui Qin, Stephen L. Chan, Wattana Sukeepaisarnjaroen, Therapeutic Advances in Medical Oncology	2019	58
The Aurora kinase inhibitor VE-465 has anticancer effects in pre-clinical studies of human hepatocellular carcinoma Zhong-Zhe Lin, Hey-Chi Hsu, Chih‐Hung Hsu, Journal of Hepatology Human Hepatocellular CarcinomaMedicinePre-clinical StudiesPathologyLiver Cancer	2008	45
Efficacy, Safety, and Potential Biomarkers of Thalidomide plus Metronomic Chemotherapy for Advanced Hepatocellular Carcinoma Yu‐Yun Shao, Zhong-Zhe Lin, Chiun Hsu, Oncology	2012	29
Chemotherapy Response in East Asian Non-small Cell Lung Cancer Patients Harboring Wild-Type or Activating Mutation of Epidermal Growth Factor Receptors Chia‐Chi Lin, Hsin-Hsin Hsu, Chia-Tung Sun, Journal of Thoracic Oncology Activating MutationChemotherapy ResponseMedicinePathologyBronchial Neoplasm	2010	29
High efficacy of erlotinib in Taiwanese NSCLC patients in an expanded access program study previously treated with chemotherapy Reury-Perng Perng, James Chih‐Hsin Yang, Yuh-Min Chen, Lung Cancer MedicineTaiwanese Nsclc PatientsCancer ManagementPharmacologyPharmacotherapy	2008	26
Phase Ib study of codrituzumab in combination with sorafenib in patients with non-curable advanced hepatocellular carcinoma (HCC) Ghassan K. Abou‐Alfa, Chia-Jui Yen, Chih‐Hung Hsu, Cancer Chemotherapy and Pharmacology Phase Ib StudyHepatologyMedicinePathologyLiver Disease	2017	26
Eg5 as a Prognostic Biomarker and Potential Therapeutic Target for Hepatocellular Carcinoma Yu‐Yun Shao, Nai-Yun Sun, Yung‐Ming Jeng, Cells	2021	19
Phase II Multicentered Study of Low-Dose Everolimus plus Cisplatin and Weekly 24-Hour Infusion of High-Dose 5-Fluorouracil and Leucovorin as First-Line Treatment for Patients with Advanced Gastric Cancer Ying‐Chun Shen, Chung‐Pin Li, Chia-Jui Yen, Oncology	2014	18

Page 1